Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Nicholas Hewlett, head of St Dunstan’s College
Highcliffe Chess Club
A friendly, local club for social and tournament players